PRISMAP outcomes

PRISMAP produces a wide range of results that we make available to you:

As a research project, PRISMAP publishes results in peer-reviewed scientific journals and other non peer-reviewed venues, and also makes detailed reports – called 'deliverables' – available, if they can be made publicly accessible.

We also make available recordings of the webinars and training sessions organised by PRISMAP, along with the material created to describe the project and how it works.

You can also find links to our funded projects page and to our educational resources, which are part of our multi-faceted outcomes.

Publications by the PRISMAP project

Publishable summary

Download the latest project summary detailing the status of PRISMAP as prepared for the EU funding body and the public.

PRISMAP sustainability white paper

As PRISMAP aims for long-term sustainability, this white paper identifies different directions to further develop access services and prepare for a mature European medical radionuclide programme PRISMAP+. Here we make a publishable extract of it available.

Public deliverables

Deliverables are reports to the EU funding body on the results achieved for one or more project tasks.
1.
White Paper on Emerging Facilities for Production of Novel Radionuclides for Use in Nuclear Medicine.
(2025). doi:10.5281/ZENODO.17257279
2.
PRISMAP workshops.
(2025). doi:10.5281/ZENODO.17458154
3.
Safety data collection for clinical translation.
(2025). doi:10.5281/ZENODO.17253347
4.
User Meetings.
(2025). doi:10.5281/ZENODO.16871554
5.
Quality data collection for clinical translation.
(2025). doi:10.5281/ZENODO.16612998
6.
Report on ion source with increased throughput.
(2025). doi:10.5281/ZENODO.16616807
7.
Academia meets industry events.
(2025). doi:10.5281/ZENODO.17457553
8.
Precision nuclear data for extended radionuclide offer.
(2025). doi:10.5281/ZENODO.15348568
9.
Training events for young researchers.
(2025). doi:10.5281/ZENODO.15410805
10.
Report on Gd target production.
(2024). doi:10.5281/ZENODO.11110642
11.
Workshops for senior researchers.
(2024). doi:10.5281/ZENODO.11842111
12.
Database of packages, documents, approvals.
(2024). doi:10.5281/ZENODO.11109988
13.
Traceability for radionuclides.
(2024). doi:10.5281/ZENODO.11093646
14.
Standardised access procedures.
(2024). doi:10.5281/ZENODO.11109550
15.
Report on precursor synthesis and related infrared spectroscopy measurements.
(2023). doi:10.5281/ZENODO.10091918
16.
Compliant and efficient transportation.
(2023). doi:10.5281/ZENODO.10069352
17.
MOOC on the basis of In the Heart of Medical Radioactivity.
(2023). doi:10.5281/ZENODO.10057649
18.
Nuclear data for day-1 radionuclides.
(2023). doi:10.5281/ZENODO.8247129
19.
Proceedings book workshop 1.
(2023). doi:10.5281/ZENODO.7913190
20.
Questionnaire on industrial and clinical key players and needs.
(2022). doi:10.5281/ZENODO.7154340
21.
First public report from the PRISMAP work package 9 (WP9, transport and logistics).
(2022). doi:10.5281/ZENODO.6606494
22.
Standards for clinical translation.
(2022). doi:10.5281/ZENODO.6599181
23.
DFT calculations for Ca and Ti containing molecules.
(2022). doi:10.5281/ZENODO.6607408

Scientific publications

Publications in peer-reviewed journals, conference proceedings, book chapters and books.
1.
Navigating the safety profile of Actinium-225 targeted alpha therapy: a comprehensive review.
Clinical and Translational Imaging (2025). doi:10.1007/s40336-025-00733-9. Archive: zenodo
2.
Validation of ICP-OES and γ-spectrometry methodologies for quality assessment of 67Cu from cyclotron production via the 70Zn(p,α)67Cu nuclear reaction.
Journal of Radioanalytical and Nuclear Chemistry 334, 5637–5648 (2025). doi:10.1007/s10967-025-10270-4. Archive: Orbit
3.
To be GMP or not to be– a radionuclide’s question.
EJNMMI Radiopharmacy and Chemistry 10, (2025). doi:10.1186/s41181-025-00369-0. Archive: pubmed
4.
Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS.
Scientific Reports 15, (2025). doi:10.1038/s41598-025-02277-4. Archive: PMC
5.
Electron-gamma decay spectroscopy of152 Tb.
Physica Scripta 100, 065308 (2025). doi:10.1088/1402-4896/add812. Archive: zenodo
6.
Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161.
EJNMMI Radiopharmacy and Chemistry 10, 18 (2025). doi:10.1186/s41181-025-00339-6. Archive: pubmed
7.
Nanolayer of Monocrystalline Si Towards Nanodosimetry of Electron Radiation.
in Joint 20th Nordic-Baltic Conference on Biomedical Engineering & 24th Polish Conference on Biocybernetics and Biomedical Engineering (eds. Ladyzynski, P., Pijanowska, D. G. & Liebert, A.) 131, 267–277 (Springer Nature Switzerland, 2025). Archive: OUCI
8.
Towards complete decay spectroscopy of 152Tb.
Radiation Physics and Chemistry 232, 112641 (2025). doi:10.1016/j.radphyschem.2025.112641. Archive: zenodo
9.
Production of 67Cu at a biomedical cyclotron via 70Zn(p,α)67Cu reaction and its evaluation in a preclinical study using small animal SPECT/CT.
Applied Radiation and Isotopes 215, 111551 (2025). doi:10.1016/j.apradiso.2024.111551. Archive: Orbit
10.
Two-step extraction chromatography separation of 161Tb from 160Gd-enriched irradiated target material and verification of the [161Tb]TbCl3 suitability for radiolabelling.
Applied Radiation and Isotopes 226, 112144 (2025). doi:10.1016/j.apradiso.2025.112144. Archive: PMC
11.
Novel radionuclides: demand, production and distribution for translational research in Europe.
EJNMMI Radiopharmacy and Chemistry 9, 85 (2024). doi:10.1186/s41181-024-00318-3. Archive: pubmed
12.
Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting 43Sc, 61Cu and 45Ti.
EJNMMI Physics 11, 98 (2024). doi:10.1186/s40658-024-00699-z. Archive: PMC
13.
First ion source at ISOL@MYRRHA with an improved thermal profile - Theoretical considerations.
Journal of Physics: Conference Series 2743, 012065 (2024). doi:10.1088/1742-6596/2743/1/012065. Archive: LIRIAS
14.
Target Development towards First Production of High-Molar- Activity 44gSc and 47Sc by Mass Separation at CERN-MEDICIS.
Pharmaceuticals 17, 390 (2024). doi:10.3390/ph17030390. Archive: PMC
15.
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework.
EJNMMI Radiopharmacy and Chemistry 9, 2 (2024). doi:10.1186/s41181-023-00230-2. Archive: PMC
16.
Synthesis and Preclinical Evaluation of PSMA-Targeted 111 In-Radioconjugates Containing a Mitochondria-Tropic Triphenylphosphonium Carrier.
Molecular Pharmaceutics 21, 216–233 (2024). doi:10.1021/acs.molpharmaceut.3c00787. Archive: SCHOLAR
17.
CERN-MEDICIS: Operational indicators to support the production of new medical radionuclides by mass-separation.
Journal of Physics: Conference Series 2687, 082039 (2024). doi:10.1088/1742-6596/2687/8/082039. Archive: LIRIAS
18.
The SPES laser ion source: Time structure, laser enhancement and efficiency measurements with gallium at ISOLDE Offline 2.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 548, 165249 (2024). doi:10.1016/j.nimb.2024.165249. Archive: CDS
19.
Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.
Nuclear Medicine and Biology 108990 (2024). doi:10.1016/j.nucmedbio.2024.108990. Archive: zenodo
20.
Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Theranostics 14, 1720–1743 (2024). doi:10.7150/thno.92775. Archive: PMC
21.
Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide.
Frontiers in Chemistry 11, 1288588 (2023). doi:10.3389/fchem.2023.1288588. Archive: BORIS
22.
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?.
EJNMMI Radiopharmacy and Chemistry 8, 27 (2023). doi:10.1186/s41181-023-00211-5. Archive: PMC
23.
Resonant laser ionization and mass separation of 225Ac.
Scientific Reports 13, 1347 (2023). doi:10.1038/s41598-023-28299-4. Archive: CDS
24.
DFT calculations of Ti-based molecules clustering with Ar for laser-based enrichment of stable isotopes.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 141–143 (2023). doi:10.1016/j.nimb.2023.05.040. Archive: CDS
25.
Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 542, 137–143 (2023). doi:10.1016/j.nimb.2023.05.008. Archive: CDS
26.
Weak Electron Emission of Nanodiamond Irradiated with High Energy Electrons.
in 19th Nordic-Baltic Conference on Biomedical Engineering and Medical Physics (eds. Dekhtyar, Y. & Saknite, I.) 89, 293–303 (Springer Nature Switzerland, 2023). https://link.springer.com/10.1007/978-3-031-37132-5_37.
27.
Determination of the Terbium-152 half-life from mass-separated samples from CERN-ISOLDE and assessment of the radionuclide purity.
Applied Radiation and Isotopes 202, 111044 (2023). doi:10.1016/j.apradiso.2023.111044. Archive: PMC
28.
First on-line application of the high-resolution spectroscopy laser ion source PI-LIST at ISOLDE.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 8–12 (2023). doi:10.1016/j.nimb.2023.04.057
29.
On the feasibility of online terbium extraction at ISOL@MYRRHA.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 249–252 (2023). doi:10.1016/j.nimb.2023.05.034
30.
Can we reach suitable 161Tb purity for medical applications using the 160Gd(d,n) reaction?.
Applied Radiation and Isotopes 200, 110927 (2023). doi:10.1016/j.apradiso.2023.110927. Archive: HAL
31.
Improved procedures for production and purification of 135La from enriched [135Ba]BaCO3 on a 16.5 MeV cyclotron.
Applied Radiation and Isotopes 192, 110612 (2023). doi:10.1016/j.apradiso.2022.110612. Archive: DTU Orbit
32.
Study of terbium production from enriched Gd targets via the reaction 155Gd(d,2n)155Tb.
Applied Radiation and Isotopes 201, 110996 (2023). doi:10.1016/j.apradiso.2023.110996. Archive: HAL
33.
Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State.
Diagnostics 12, 3176 (2022). doi:10.3390/diagnostics12123176. Archive: PMC
34.
Thermal and Structural Characterization of a Titanium Carbide/Carbon Composite for Nuclear Applications.
Materials 15, 8358 (2022). doi:10.3390/ma15238358. Archive: PMC
35.
Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [153Sm]Sm-DOTA-TATE.
Pharmaceutics 14, 2566 (2022). doi:10.3390/pharmaceutics14122566. Archive: SCK CEN Publications
36.
Excitation functions of deuteron induced nuclear reactions on dysprosium targets for the production of the theranostic relevant isotopes of terbium.
The European Physical Journal Plus 137, 1180 (2022). doi:10.1140/epjp/s13360-022-03378-z. Archive: HAL
37.
67Cu Production Capabilities: A Mini Review.
Molecules 27, 1501 (2022). doi:10.3390/molecules27051501. Archive: PMC
38.
Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS.
Applied Radiation and Isotopes 190, 110480 (2022). doi:10.1016/j.apradiso.2022.110480. Archive: cds
39.
Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS.
Frontiers in Medicine 8, 712374 (2021). doi:10.3389/fmed.2021.712374. Archive: PMC
40.
Emerging Radionuclides in a Regulatory Framework for Medicinal Products – How Do They Fit?.
Frontiers in Medicine 8, 678452 (2021). doi:10.3389/fmed.2021.678452. Archive: PMC
41.
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy.
Journal of Nuclear Medicine 62, 1495–1503 (2021). doi:10.2967/jnumed.120.261016. Archive: PMC
 

Publications by the funded projects

PRISMAP selects projects for funding and serves as provider of radionuclides and medical application services for these projects.

The selected projects are presented on our access platform with title, leader, keywords, a publishable abstract and, if available, a summary of the results and a list of related publications.

1.
A true theranostic pair – 44/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer.
European Journal of Nuclear Medicine and Molecular Imaging (2025). doi: 10.1007/s00259-025-07651-y. Archive: pubmed
2.
Optimised solid-phase extraction of 211At: Activity balance of 211At, 210At and 210Po after wet chemistry target dissolution.
Radiation Physics and Chemistry 225, 112146 (2024). doi: 10.1016/j.radphyschem.2024.112146. Archive: scopus
3.
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161 Tb and 177 Lu: A Comparative Study.
Journal of Nuclear Medicine jnumed.123.266233 (2023). doi: 10.2967/jnumed.123.266233. Archive: pubmed

Webinars and trainings

PRISMAP provides training for the highly multidisciplinary and fragmented research community.

A common understanding and common terms will enable users, service providers and regulators to speak the same language.

Recordings of previous webinars promoted by PRISMAP look at production of radionuclides, regulatory aspects, theranostics.

For a full list of events, webinars and training sessions organised by the project, please visit our events page.

Project presentation

With this series of short videos and the flyer, we would like to introduce the project, its goals and its way of working to a wide audience.

Educational content

PRISMAP offers education and training resources aimed at high school or early university students, but anyone is welcome to use them.

The available information can be downloaded from the dedicated educational resources section of our website and freely used in educational settings.